BioNexus Gene Lab (BGLC) announces MyCIF co-investment in AISB, total round RM 1.7M (~$390k)

BioNexus Gene Lab Corp

Malaysian Securities Commission co-invests alongside BGLC in Ascension Innovation under ESI scheme; total round RM 1.7M (~USD 390k).
BGLC previously invested RM 1M; AISB is first recipient of MyCIF ESI scheme.
Proceeds to advance AI-driven healthcare platform aiCMS and support Malaysia's National EMR Plan 'One Patient, One Record'.
CEO Sam Tan cites confidence from government investment in AISB's technology and BGLC's strategic direction.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.